- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03482167
NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment
January 22, 2024 updated by: Christopher Martens, University of Delaware
This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities.
Overall, this project has the potential to identify a novel, safe and cost-effective strategy for decreasing age-related memory loss.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Catherine Awad, B.S.
- Phone Number: 302-831-8137
- Email: chs-novalab@udel.edu
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Neurovascular Aging Laboratory
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
- Cognitive function scores consistent with amnestic mild cognitive impairment based on pre-screening evaluation;
- age 60-90 years;
- MMSE score >24 at time of initial consent;
Exclusion Criteria
- blood chemistries indicative of abnormal renal, liver, thyroid and adrenal function; estimated glomerular filtration rate using the MDRD prediction equation must be >30 ml/min/1.73 m2;
- any clinically significant abnormal blood chemistry values as determined by the research nurse or NMPCC nurse practitioner;
- major psychiatric disorder (e.g. schizophrenia, bipolar disorder, major depression within past two years);
- neurological or autoimmune conditions affecting cognition (e.g. Parkinson's disease, epilepsy, multiple sclerosis, mild or severe traumatic brain injury, large vessel infarct);
- concussion within last 2 years and ≥ 3 lifetime concussions;
- current systemic medical illnesses (e.g. cardiovascular disease, cancer, renal failure);
- prior history of any type of cancer;
- substance abuse or dependence (DSM-V criteria);
- current use of medications used to treat dementia (e.g., anticholinesterase drugs) or other drugs likely to affect cognition (e.g., anticholinergic drugs, long-acting benzodiazepines);
- claustrophobia, metal implants, pacemaker or other factors affecting feasibility and/or safety of MRI scanning*;
- current smoking (including marijuana) within the past 3 months;
- hospitalization as a result of COVID-19
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
placebo
|
placebo
|
Experimental: Nicotinamide Riboside
Niagen® (ChromaDex, Inc.) 500 mg, twice daily
|
250 mg capsules (4 capsules daily)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in cognitive scores at 12 weeks
Time Frame: baseline and 12 weeks
|
change in one or more domains of cognitive function including: episodic memory, attention, working memory, processing speed, executive function and language abilities from baseline
|
baseline and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in cerebrovascular reactivity at 12 weeks
Time Frame: baseline and 12 weeks
|
Cerebrovascular reactivity to hypercapnia
|
baseline and 12 weeks
|
Change from baseline in total brain blood flow at 12 weeks
Time Frame: baseline and 12 weeks
|
Total brain blood flow
|
baseline and 12 weeks
|
Change from baseline in aortic stiffness at 12 weeks
Time Frame: baseline and 12 weeks
|
Carotid-femoral pulse wave velocity (CFPWV)
|
baseline and 12 weeks
|
Change from baseline in blood pressure at 12 weeks
Time Frame: baseline and 12 weeks
|
systolic and diastolic blood pressure
|
baseline and 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in neurovascular coupling at 12 weeks
Time Frame: baseline and 12 weeks
|
Cerebrovascular reactivity to cognitive tasks
|
baseline and 12 weeks
|
Change from baseline in functional brain connectivity at 12 weeks
Time Frame: baseline and 12 weeks
|
functional brain connectivity assessed by MRI
|
baseline and 12 weeks
|
Change from baseline in neuronal activation at 12 weeks
Time Frame: baseline and 12 weeks
|
Functional MRI (fMRI) to cognitive task
|
baseline and 12 weeks
|
Change from baseline in brain volume at 12 weeks
Time Frame: baseline and 12 weeks
|
White and grey matter volume assessed by structural MRI
|
baseline and 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Christopher R Martens, Ph.D., University of Delaware
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2018
Primary Completion (Actual)
January 8, 2024
Study Completion (Actual)
January 22, 2024
Study Registration Dates
First Submitted
February 14, 2018
First Submitted That Met QC Criteria
March 22, 2018
First Posted (Actual)
March 29, 2018
Study Record Updates
Last Update Posted (Actual)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 22, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1079271
- K01AG054731 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RecruitingMild Cognitive Impairment (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute on Aging... and other collaboratorsCompletedMild Cognitive Impairment (MCI)United States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Meir Medical CenterTerminatedMild Cognitive Impairment (MCI)Israel
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States